Sopharma AD notifies that for January 2018 the Company recorded an increase of sales revenues of 3% compared to the same month of 2017, including 5% increase of export sales and same level of domestic sales.

Sopharma AD ended its most successful financial year after the crisis. 2017 ended with 12.5% revenue growth reaching 205.3 million BGN, 44.8% increase in operating profit, 30.7% EBITDA growth and almost 10% growth in net profit.

During this successful year, the company took two important investment decisions, namely to start the construction of:

1. An extraction plant in Kazanlak, which will allow more effective and modern production of all phyto products and

Sopharma AD received a notification for the sale of 250 000 shares, representing 0.19% of its capital, by CUPF Allianz Bulgaria. After the transaction the share of CUPF Allianz Bulgaria in the capital of Sopharma AD reached 4.99%.

The date of the registration of the transaction with the Central Depository is 24 January 2018.